# US 2024/0199735 A1 · Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199735 A1
- Document ID: US20240199735A1
- Status: Published application
- Kind: A1
- Application number: 16/936,421
- Filed: 2020-07-22
- Published: 2024-06-20
- Earliest claimed: 2019-07-22
- Assignees: The Methodist Hospital; Board of Regents, The University of Texas System
- Applicants: The Methodist Hospital; Board of Regents, The University of Texas System
- Inventors: Stephen T.C. WONG; Jianting SHENG; Samuel C. MOK; Cecilia S. LEUNG; Tsz-Lun YEUNG
- Web page: https://patentgrep.com/patent/US20240199735A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 33/243: Platinum; Compounds thereof
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- G01N 33/57545: of the ovaries
- G01N 33/582: {with fluorescent label}
- G01N 33/60: involving radioactive labelled substances
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are antibody compositions and methods for treatment mammalian cancers. Also disclosed are methods for use of the disclosed MFAP5-specific monoclonal antibodies and antigen-binding-fragments thereof, in the treatment, prophylaxis, and/or the amelioration of one or more symptoms of mammalian cancer, including human ovarian and pancreatic cancers, in particular.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A isolated antibody or an antigen-binding fragment thereof, comprising:
(i) a Variable Heavy Chain (VH) domain comprising a polypeptide sequence that is at least 95% identical to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:13; and
(ii) a Variable Light Chain (VL) domain comprising a polypeptide sequence that is at least 95% identical to SEQ ID NO:14 or SEQ ID NO:15.

### Claim 30 (depends on 29)

The isolated antibody or an antigen-binding fragment thereof of claim 29, wherein the Variable Heavy Chain (VH) domain comprises a polypeptide sequence that is at least 97% identical to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:13.

### Claim 31 (depends on 29)

The isolated antibody or an antigen-binding fragment thereof of claim 29, wherein the Variable Light Chain (VL) domain comprises a polypeptide sequence that is at least 97% identical to SEQ ID NO:14 or SEQ ID NO:15.

### Claim 32 (depends on 29)

The isolated antibody or an antigen-binding fragment thereof of claim 29, wherein the Variable Heavy Chain (VH) domain comprises a polypeptide sequence that is at least 99% identical to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:13.

### Claim 33 (depends on 29)

The isolated antibody or an antigen-binding fragment thereof of claim 29, wherein the Variable Light Chain (VL) domain comprises a polypeptide sequence that is at least 99% identical to SEQ ID NO:14 or SEQ ID NO:15.

### Claim 34 (depends on 29)

A composition, comprising:
the isolated antibody or the antigen-binding fragment of claim 29; and
a pharmaceutically-acceptable buffer, diluent, carrier, or vehicle.

### Claim 35 (depends on 34)

The composition of claim 34, further comprising an adjuvant.

### Claim 36 (depends on 34)

The composition of claim 34, further comprising a chemotherapeutic agent, an immunomodulating agent, a neuroactive agent, an anti-inflammatory agent, an anti-lipidemic agent, a hormone, a receptor agonist, a receptor antagonist, an anti-infective agent, a protein, a peptide, an antibody, an antigen-binding fragment of an antibody, an RNA molecule, a DNA molecule, an siRNA molecule, an mRNA molecule, a ribozyme, a hormone, a cofactor, a steroid, an antisense nucleic acid, or any combination of any thereof.

### Claim 37 (depends on 36)

The composition of claim 36, wherein the chemotherapeutic agentic comprises one or more antineoplastic compounds, one or more cytotoxic compounds, one or more cytostatic compounds, or any combination of any thereof.

### Claim 38 (depends on 36)

The composition of claim 36, wherein the chemotherapeutic agent is cyclophosphamide, doxorubicin, 5 fluorouracil, docetaxel, paclitaxel, trastuzumab, methotrexate, epirubicin, cisplatin, carboplatin, vinorelbine, capecitabine, gemcitabine, mitoxantrone, isabepilone, eribulin, lapatinib, carmustine, a nitrogen mustard, a sulfur mustard, a platin tetranitrate, vinblastine, etoposide, camptothecin, or any combination of any thereof.

### Claim 39 (depends on 29)

A kit, comprising:
a composition, comprising the isolated antibody or antigen-binding fragment thereof of claim 29; and
instructions for administering a composition to a subject in need thereof, as part of a regimen for the prevention, diagnosis, treatment, or amelioration of one or more symptoms of cancer.

### Claim 40 (depends on 29)

A method of treating or ameliorating one or more symptoms of cancer in a subject in need thereof, the method comprising:
administering to the subject an effective amount of the isolated antibody or antigen-binding fragment thereof of claim 29 for a time sufficient to treat or ameliorate the one or more symptoms of the cancer in the subject.

### Claim 41 (depends on 40)

The method of claim 40, wherein the cancer is a refractory, a metastatic, a relapsed, or a treatment resistant cancer.

### Claim 42 (depends on 40)

The method of claim 40, wherein the cancer is a tumorigenic cancer.

### Claim 43 (depends on 42)

The method of claim 42, wherein the cancer is ovarian cancer or pancreatic cancer.

### Claim 44 (depends on 40)

The method of claim 40, wherein the subject is a mammal.

### Claim 45 (depends on 40)

The method of claim 40, further comprising administering a therapeutically effective amount of ionizing radiation, a second distinct antibody, a second distinct chemotherapeutic agent, or any combination of any thereof, to the subject.

### Claim 46 (depends on 29)

A method of reducing a level of biologically-active MFAP5 polypeptide in a subject in need thereof, the method comprising:
administering to the subject in need thereof the isolated antibody or antigen-binding fragment of claim 29 in an amount effective and for a time sufficient to reduce the level of biologically-active MFAP5 polypeptide in the subject in need thereof.

### Claim 47 (depends on 46)

The method of claim 46, wherein the subject in need thereof has a cancer that is a refractory, a metastatic, a relapsed, or a treatment resistant cancer.

### Claim 48 (depends on 46)

The method of claim 46, wherein the subject in need thereof has been diagnosed with a tumorigenic cancer.

### Claim 49 (depends on 48)

The method of claim 48, wherein the cancer is ovarian cancer or pancreatic cancer.

### Claim 50 (depends on 29)

A method of reducing the degree of fibrosis or the extent of collagen development in the tumor microenvironment of a subject diagnosed with cancer, comprising:
administering to the subject the isolated antibody or antigen-binding fragment of claim 29 in an amount effective and for a time sufficient to reduce the degree of fibrosis or the extent of collagen development in the subject.

### Claim 51 (depends on 50)

The method of claim 50, wherein the cancer is a refractory, a metastatic, a relapsed, or a treatment resistant cancer.

### Claim 52 (depends on 51)

The method of claim 51, wherein the subject in need thereof has been diagnosed with a tumorigenic cancer.

### Claim 53 (depends on 52)

The method of claim 52, wherein the subject has been diagnosed with ovarian cancer or pancreatic cancer.

### Claim 54 (depends on 29)

A method for inhibiting cancer cell motility or suppressing tumor progression in a subject, comprising:
administering to the subject the isolated antibody or antigen-binding fragment of claim 29 in an amount effective and for a time sufficient to inhibit motility of one or more cancer cells or to suppress progression of one or more tumors in the subject.

### Claim 55 (depends on 54)

The method of claim 54, wherein the one or more cancer cells are ovarian cancer cells or pancreatic cancer cells or where in the one or more tumors are pancreatic tumors or ovarian tumors.

### Claim 56 (depends on 29)

A diagnostic composition, comprising
the isolated antibody or the antigen-binding fragment of claim 29, and
a detectable label.

### Claim 57 (depends on 56)

The diagnostic composition of claim 56, wherein the detectable label is a radiolabel or reporter agent detectable by immunofluorescence.
